Download PDF
Hamostaseologie 2020; 40(05): 662-670
DOI: 10.1055/a-1223-3367
Original Article

Antiphospholipid Antibodies Are Not Associated with Clinical Parameters or Prognostic Outcomes in Patients with Non-Hodgkin's Lymphoma

Rimesh Pal
1   Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Subhash Varma
1   Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Jasmina Ahluwalia
2   Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Gaurav Prakash
1   Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
› Author Affiliations Funding Sources None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Antiphospholipid antibodies (APAs) are found quite frequently in patients with non-Hodgkin’s lymphoma (NHL). However, the clinical significance of these antibodies is largely unknown. This study aims to delineate the clinical and prognostic role of APAs in NHL patients.

Patients and Methods  Consecutive patients of NHL were screened for lupus anticoagulant (LA), IgG/IgM anticardiolipin antibody, and IgG/IgM anti-β2-glycoprotein I at the time of diagnosis. Baseline investigations, staging, and treatment were done as per institutional protocol. Patients were followed up until the last known outpatient visit or death. All were screened at each visit for any thromboembolic event. The association of APA status with baseline NHL characteristics and treatment response was evaluated by univariate analysis. Kaplan–Meier survival analysis was used to compare the final outcome in patients with or without APAs. Patients who were initially APA positive were retested for the corresponding antibody at the end of chemotherapy.

Results Twenty-four out of 105 patients (22.8%) were APA positive at diagnosis. The presence of APA was not significantly associated with NHL stage, histology, International Prognostic Index score, activated partial thromboplastin time, or treatment response. The median duration of follow-up was 15 months. Only four patients developed venous thrombosis; none was APA positive. There was no statistically significant difference in overall survival between the two groups (p = 0.471). Patients, who were APA positive initially, tested negative at the end of treatment, irrespective of treatment response.

Conclusion APAs are encountered more frequently in NHL patients than in the general population. However, APAs do not correlate with disease severity, thrombosis risk, treatment outcome, or overall survival.

Zusammenfassung

Antiphospholipid-Antikörper (APAs) treten häufig bei Non-Hodgkin-Lymphom-Patienten (NHL) auf, ihre genaue Rolle ist jedoch unklar. Wir verfolgten prospektiv 105 NHL-Patienten über eine mittlere Dauer von 15 Monaten. Antiphospholipid-Antikörper wurden bei 22,8% der NHL-Patienten nachgewiesen, eine Prävalenzrate, die viel höher ist als die der Allgemeinbevölkerung. Neunzehn (79%) waren positiv für einen einzelnen Antikörper, während fünf (21%) positiv für zwei Antikörper waren. Anti-β2-Glykoprotein I war das am häufigsten nachgewiesene APA, gefolgt von Lupus-Antikoagulans und Anti-Cardiolipin-Antikörper. Die mittlere aktivierte partielle Thromboplastinzeit unterschied sich nicht zwischen den APA-positiven und den APA-negativen Gruppen. Nur 4 Patienten (3,8%) hatten eine Venenthrombose entwickelt; Keiner war positiv für APAs. Der Status des Antiphospholipid-Antikörpers korrelierte nicht mit dem Krankheitsstadium, der Histologie, dem International Prognostic Index oder dem Ansprechen auf die Behandlung. Die Kaplan-Meier-Überlebensanalyse zeigte keinen statistisch signifikanten Überlebensunterschied zwischen APA-positiven und APA-negativen Patienten. Es wurde festgestellt, dass nur der Leistungsstatus das Überleben signifikant vorhersagt.

Keywords

non-Hodgkin's lymphoma - antiphospholipid antibodies - lupus anticoagulant - anticardiolipin antibody - anti-β2-glycoprotein I

Schlüsselwörter

Non-Hodgkin-Lymphom - Antiphospholipid-Antikörper - Lupus-Antikoagulans - Anti-Cardiolipin-Antikörper - Anti-β2-Glykoprotein I

Conflict of Interest

The authors have no conflicts of interest to declare.


Supplementary Material



Publication History

Received: 29 April 2020

Accepted: 20 July 2020

Article published online:
15 September 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Bruce IN, Clark-Soloninka CA, Spitzer KA, Gladman DD, Urowitz MB, Laskin CA. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol 2000; 27 (12) 2833-2837
    PubMedGoogle Scholar
  • 2 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
    CrossrefPubMedGoogle Scholar
  • 3 Zuckerman E, Toubi E, Golan TD. et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995; 72 (02) 447-451
    CrossrefPubMedGoogle Scholar
  • 4 Ottinger H, Belka C, Kozole G. et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995; 54 (03) 186-194
    CrossrefPubMedGoogle Scholar
  • 5 Stasi R, Stipa E, Masi M. et al. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma. Thromb Haemost 1993; 70 (04) 568-572
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Timurağaoğlu A, Duman A, Ongüt G, Saka O, Karadoğan I. The significance of autoantibodies in non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 40 (1-2): 119-122
    CrossrefPubMedGoogle Scholar
  • 7 Bairey O, Blickstein D, Monselise Y. et al. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006; 76 (05) 384-391
    CrossrefPubMedGoogle Scholar
  • 8 Oken MM, Creech RH, Tormey DC. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (06) 649-655
    CrossrefPubMedGoogle Scholar
  • 9 International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329 (14) 987-994
    CrossrefPubMedGoogle Scholar
  • 10 Minna JD, Bunn Jr PA. Paraneoplastic syndromes. In: Cancer: Principles and Practice of Oncology. VT DeVita Jr, S Hellman, SA Rosenberg, eds. Philadelphia: JB Lippincott Company; 1989: 1920-1940
    Google Scholar
  • 11 Naschitz JE, Yeshurun D, Lev LM. Thromboembolism in cancer. Changing trends. Cancer 1993; 71 (04) 1384-1390
    CrossrefPubMedGoogle Scholar
  • 12 Al-Mondhiry H, McGarvey V. Tumor interaction with vascular endothelium. Haemostasis 1987; 17 (05) 245-253
    PubMedGoogle Scholar
  • 13 Alarcón-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16 (04) 482-488
    PubMedGoogle Scholar
  • 14 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314 (18) 1193-1194
    CrossrefPubMedGoogle Scholar
  • 15 Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev 2010; 9 (04) 200-202
    CrossrefPubMedGoogle Scholar
  • 16 Gómez-Puerta JA, Cervera R, Espinosa G. et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006; 35 (05) 322-332
    CrossrefPubMedGoogle Scholar
  • 17 Gómez-Puerta JA, Espinosa G, Cervera R. Antiphospholipid antibodies: from general concepts to its relation with malignancies. Antibodies (Basel) 2016; 5 (03) 18
    CrossrefPubMedGoogle Scholar
  • 18 Vassalo J, Spector N, de Meis E. et al. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. J Crit Care 2014; 29 (04) 533-538
    CrossrefPubMedGoogle Scholar
  • 19 Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 2003; 12 (02) 112-116
    CrossrefPubMedGoogle Scholar
  • 20 Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 2006; 25 (06) 840-844
    CrossrefPubMedGoogle Scholar
  • 21 Bazzan M, Montaruli B, Vaccarino A, Fornari G, Saitta M, Prandoni P. Presence of low titre of antiphospholipid antibodies in cancer patients: a prospective study. Intern Emerg Med 2009; 4 (06) 491-495
    CrossrefPubMedGoogle Scholar
  • 22 Onida P, Tresoldi M, Rugarli C. Anti-phospholipid-antibody syndrome associated with peripheral T-cell lymphoma. Am J Hematol 1997; 55 (03) 167-168
    CrossrefPubMedGoogle Scholar
  • 23 Keung YK, Cobos E, Meyerrose GE, Roberson GH. Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant. Leuk Lymphoma 1996; 20 (3-4): 341-345
    CrossrefPubMedGoogle Scholar
  • 24 Gruber ML, Hochberg FH. Visual scotomata resulting from lupus anticoagulant in a patient with lymphoma in remission. J Neurooncol 1991; 11 (01) 77-79
    CrossrefPubMedGoogle Scholar
  • 25 Sciarra A, Stasi R, Stipa E. et al. Antiphospholipid antibodies: their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma. [in Italian]. Recenti Prog Med 1995; 86 (02) 57-62
    PubMedGoogle Scholar
  • 26 Pusterla S, Previtali S, Marziali S. et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004; 5 (04) 341-346
    CrossrefPubMedGoogle Scholar
  • 27 Saber MM. The clinical significance of both IgM and IgG anticardiolipin antibodies in non-Hodgkin's lymphoma. J Clin Cell Immunol 2016; 7 (03) DOI: 10.4172/2155-9899.1000436.
    CrossrefPubMedGoogle Scholar
  • 28 Tanne D, Levine SR, Kittner SJ. Epidemiology of antiphospholipid antibodies and vascular disease. In: Levine SR, Brey RL. eds. Clinical Approach to Antiphospholipid Antibodies. Boston, MA: Butterworth Heinemann; 2000: 1-18
    Google Scholar
  • 29 Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases. Br J Haematol 2004; 124 (02) 151-159
    CrossrefPubMedGoogle Scholar
  • 30 Viard JP, Amoura Z, Bach JF. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93 (02) 181-186
    CrossrefPubMedGoogle Scholar
  • 31 Gómez-Pacheco L, Villa AR, Drenkard C, Cabiedes J, Cabral AR, Alarcón-Segovia D. Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999; 106 (04) 417-423
    CrossrefPubMedGoogle Scholar
  • 32 Genvresse I, Buttgereit F, Späth-Schwalbe E, Ziemer S, Eucker J, Possinger K. Arterial thrombosis associated with anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma: a report of two cases. Eur J Haematol 2000; 65 (05) 344-347
    CrossrefPubMedGoogle Scholar
  • 33 Saber MM. The clinical significance of both IgM and IgG anti-cardiolipin antibodies in non-Hodgkin’s lymphoma. J Clin Cell Immunol 2016; 7 (3). DOI: 10.4172/2155-9899.1000436.
    CrossrefPubMedGoogle Scholar